Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

• DOI: 10.1200/jco.2014.32.15_suppl.e15602
• Publication Date: 2019-01-03T22:32:22Z
• Authors: Ibrahim Yildiz; Meltem Ekenel; Tulay Akman; Muharrem Kocar; Mukremin Uysal; Metin Kanitez; Vedat Bayoglu; Umut Varol; Deniz Tural; Nilufer Avci; Muhammet Ali Kaplan; Zeki Surmeli; Isa Dede; Arife Ulas; Ozan Yazici; Mert Basaran
• Keywords: Chromophobe cell; Progression-free survival

e15602 Background: Most of the randomizedstudies that have evaluated clinical outcome anti-VEGF treatment in metastatic renal cell carcinoma (RCC) were focused mostly on clear histology. Non-clear RCC excluded or represented by a small number patients pivotal studies. In this study, our aim is to determine benefit and toxicity sunitinib non-clear patients. Methods: A total 63 who complete data from 13 oncology centers retrospectively evaluated. Treatment response, toxicity, progression free survival (PFS) overall (OS) Results: The median age was years (range, 25-82 years), study sample consisted 38 men (60.3%) 25 women (39.7%). Forty-six (88%) had histological subtype papillary while other subtypes chromophobe (n=10) unclassified (n=7). Before treatment, 55 (89%) undergone nephrectomy, 39 (61.9%) treated with cytokine-based therapy 2 cytotoxic chemotherapy. Twenty-four first-line treatment. duration 7 months 2-86 months). At time analysis, 52 discontinued 33 whom deceased. Seven (11.1%) partial response (52.4%) stable disease control rate (CR-PR-SD) %63.5 found 23 (36.5%) Median PFS 7.6 (95% CI, 5.5-9.7 months) OS 22.0 13.4-30.6 1-year 64.7%, 33.7%. Conclusions: Clinical seem be worse than historical patients, terms PFS, objective response. Different molecular pathways different subtypes, chromosomal genetic changes may affect New more effective targeted therapies understanding underlying processes are necessary improve their outcome.